Capstone Therapeutics announced that they have met the objectives of their second keloid trial for AZX100.

AZX100 is currently being evaluated for safety and efficacy of medical applications such as the prevention or reduction of hypertrophic and keloid scarring following excision of keloid scars.  Other proven clinical options for prevention of keloid scarring include application of silicone (e.g. Strataderm) after surgical resection which prevented development of hypertrophic scars and keloids in 75-85% of cases.

More information about keloid scarring:

Factors Affecting Abnormal Scarring

How to Avoid Abnormal Scars